INBX (STOCKS)
Inhibrx Biosciences, Inc. Common Stock
$82.180000
+0.190000 (+0.23%)
Prev close: $81.990000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Mark Paul Lappe
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,194.84M
- Employees
- 161
- P/E (TTM)
- -8.02
- P/B (TTM)
- 32.28
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-2.28 | $-1.75 | -0.5276 | -30.11% |
|
Jun 2025 (Q2)
|
$-1.85 | $-2.82 | +0.9662 | +34.31% |
|
Mar 2025 (Q1)
|
$-2.80 | $-2.90 | +0.0953 | +3.29% |
|
Dec 2024 (Q4)
|
$-3.09 | $-2.94 | -0.1463 | -4.97% |
Financial Statements
| Revenues | $1.78M |
| Nonoperating Income/Loss | -$20.24M |
| Operating Expenses | $251.06M |
| Research and Development | $218.11M |
| Other Operating Expenses | $32.96M |
| Operating Income/Loss | -$249.28M |
| Income/Loss From Continuing Operations After Tax | -$269.52M |
| Income/Loss From Continuing Operations Before Tax | -$269.52M |
| Income Tax Expense/Benefit | $3.00K |
| Net Income/Loss | -$271.16M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$271.16M |
| Net Income/Loss Available To Common Stockholders, Basic | -$271.16M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.44 |
| Diluted Earnings Per Share | -$5.44 |
| Basic Average Shares | 147,674,000 |
| Diluted Average Shares | 147,674,000 |
| Assets | $288.58M |
| Current Assets | $274.54M |
| Noncurrent Assets | $14.04M |
| Fixed Assets | $6.97M |
| Other Non-current Assets | $7.07M |
| Liabilities | $277.01M |
| Current Liabilities | $71.87M |
| Accounts Payable | $14.79M |
| Wages | $2.10M |
| Other Current Liabilities | $54.98M |
| Noncurrent Liabilities | $205.14M |
| Equity | $11.57M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $11.57M |
| Liabilities And Equity | $288.58M |
| Net Cash Flow From Operating Activities | -$216.42M |
| Net Cash Flow From Operating Activities, Continuing | -$216.42M |
| Net Cash Flow From Investing Activities | -$5.69M |
| Net Cash Flow From Investing Activities, Continuing | -$5.69M |
| Net Cash Flow From Financing Activities | $240.33M |
| Net Cash Flow From Financing Activities, Continuing | $240.33M |
| Net Cash Flow | $18.23M |
| Net Cash Flow, Continuing | $18.23M |
| Comprehensive Income/Loss | -$271.16M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$271.16M |
| Other Comprehensive Income/Loss | $0.00 |